The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The prognostic impact of KMT2A fusion transcript detection in patients with KMT2A-r AML in CR1
Jad Othman, MBBS, University of Sydney, Sydney, Australia, and King’s College and Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the prognostic impact of tracking KMT2A fusion transcript expression to detect measurable residual disease (MRD) in patients with KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) in remission after intensive chemotherapy. Dr Othman highlights that the detection of KMT2A fusion transcripts after induction chemotherapy is strongly predictive of outcome and that this technique may help identify patients who derive benefit from allogeneic stem cell transplantation (alloSCT) in first complete remission (CR1). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
